Stakeholders' Perspectives regarding Participation in Neuromodulation-Based Dementia Intervention Research

J Empir Res Hum Res Ethics. 2022 Feb-Apr;17(1-2):29-38. doi: 10.1177/15562646211060997. Epub 2021 Dec 6.

Abstract

This study evaluated stakeholders' perspectives regarding participation in two hypothetical neuromodulation trials focused on individuals with Alzheimer's disease and related disorders (ADRDs). Stakeholders (i.e., individuals at risk for ADRDs [n = 56], individuals with experience as a caregiver for someone with a cognitive disorder [n = 60], and comparison respondents [n = 124]) were recruited via MTurk. Primary outcomes were willingness to enroll (or enroll one's loved one), feeling lucky to have the opportunity to enroll, and feeling obligated to enroll in two protocols (transcranial magnetic stimulation, TMS; deep brain stimulation, DBS). Relative to the Comparison group, the At Risk group endorsed higher levels of "feeling lucky" regarding both research protocols, and higher willingness to participate in the TMS protocol. These findings provide tentative reassurance regarding the nature of decision making regarding neurotechnology-based research on ADRDs. Further work is needed to evaluate the full range of potential influences on research participation.

Keywords: Alzheimer’s disease; caregivers; clinical trials; cognitive disorders; decision making; dementia; neuromodulation; research participation.

MeSH terms

  • Alzheimer Disease* / therapy
  • Caregivers
  • Cognition Disorders*
  • Humans
  • Transcranial Magnetic Stimulation / methods